Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Glia ; 57(3): 258-69, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18837047

ABSTRACT

The study of ion channels has relied heavily on the use of pharmacological blocking agents. However, many of these agents have multiple effects, which may compromise interpretation of results when the affected mechanisms/pathways mediate similar functions. Volume regulated anion channels (VRAC) and connexin hemichannels can both mediate the release of glutamate and taurine, although these channels have distinct activation stimuli and hemichannels, but not VRAC, are permeable to Lucifer Yellow (LY). It has been reported that some anion channel blockers may inhibit connexin hemichannels. We further examined the effects of classic gap junction/hemichannel blockers and anion channel blockers on these channels. The typical VRAC blockers, NPPB, IAA-94, and tamoxifen blocked low divalent cation-induced glutamate and taurine release and LY loading, presumed due to hemichannel opening. The blocking action of these compounds on hemichannels was concentration dependent and fell within the same range where the drugs classically block VRACs. Conversely, carbenoxolone (CBX), the most widely used gap junction/hemichannel blocker, was an effective blocker of VRAC-mediated glutamate and taurine release, and blocked these channels at similar concentrations at which it blocked hemichannels. The CBX effect on VRACs was verified using astrocytes from connexin 43 knock out (Cx43 KO) animals. In these cells, the hypotonic induced amino acid flux was retained whereas the low divalent cation solution-induced flux was lost. These results extend our knowledge about "cross-inhibition" of VRACs and gap junctions/hemichannels by certain pharmacological agents. Given the overlap in function of these two types of channels, great care must be exerted in using pharmacological blockers to identify one channel from the other.


Subject(s)
Astrocytes/drug effects , Cell Size , Connexin 43/physiology , Ion Channel Gating/physiology , Ion Channels/physiology , Amino Acids/metabolism , Analysis of Variance , Angiogenesis Inhibitors/pharmacology , Animals , Animals, Newborn , Carbenoxolone/pharmacology , Cell Size/drug effects , Cells, Cultured , Chromatography, High Pressure Liquid/methods , Connexin 43/antagonists & inhibitors , Connexin 43/deficiency , Connexin 43/drug effects , Glycyrrhetinic Acid/analogs & derivatives , Glycyrrhetinic Acid/pharmacology , Hippocampus/cytology , Hypotonic Solutions/pharmacology , Indans/pharmacology , Ion Channel Gating/drug effects , Ion Channel Gating/genetics , Ion Channels/drug effects , Isoquinolines/metabolism , Mice , Mice, Knockout , Nitrobenzoates/pharmacology , Rats , Tamoxifen/pharmacology
2.
Stroke ; 40(3 Suppl): S8-12, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19064795

ABSTRACT

Ischemic injury is traditionally viewed from an axiomatic perspective of neuronal loss. Yet the ischemic infarct encompasses all cell types, including astrocytes. This review will discuss the idea that astrocytes play a fundamental role in the pathogenesis of ischemic neuronal death. It is proposed that stroke injury is primarily a consequence of the failure of astrocytes to support the essential metabolic needs of neurons. This "gliocentric view" of stroke injury predicts that pharmacological interventions specifically targeting neurons are unlikely to succeed, because it is not feasible to preserve neuronal viability in an environment that fails to meet essential metabolic requirements. Neuroprotective efforts targeting the functional integrity of astrocytes may constitute a superior strategy for future neuroprotection.


Subject(s)
Astrocytes/physiology , Brain Ischemia/physiopathology , Adenosine Triphosphate/physiology , Animals , Astrocytes/pathology , Brain Ischemia/pathology , Calcium Signaling/physiology , Disease Models, Animal , Humans , Rats
3.
Nat Med ; 11(9): 973-81, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16116433

ABSTRACT

Hypersynchronous neuronal firing is a hallmark of epilepsy, but the mechanisms underlying simultaneous activation of multiple neurons remains unknown. Epileptic discharges are in part initiated by a local depolarization shift that drives groups of neurons into synchronous bursting. In an attempt to define the cellular basis for hypersynchronous bursting activity, we studied the occurrence of paroxysmal depolarization shifts after suppressing synaptic activity using tetrodotoxin (TTX) and voltage-gated Ca(2+) channel blockers. Here we report that paroxysmal depolarization shifts can be initiated by release of glutamate from extrasynaptic sources or by photolysis of caged Ca(2+) in astrocytes. Two-photon imaging of live exposed cortex showed that several antiepileptic agents, including valproate, gabapentin and phenytoin, reduced the ability of astrocytes to transmit Ca(2+) signaling. Our results show an unanticipated key role for astrocytes in seizure activity. As such, these findings identify astrocytes as a proximal target for the treatment of epileptic disorders.


Subject(s)
Astrocytes/physiology , Calcium Signaling , Epilepsy/physiopathology , Glutamic Acid/metabolism , Action Potentials/drug effects , Animals , Anticonvulsants/pharmacology , Astrocytes/drug effects , Calcium Signaling/drug effects , Hippocampus , Photolysis , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...